Biopharmaceutical Excipients Market Size, Share and Growth Outlook, 2026

Biopharmaceutical Excipients Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biopharmaceutical Excipients Market size is forecast to increase from $3.9 Billion in 2026 to $5.94 Billion in 2034 at a CAGR of 5.4% between 2026 and 2034.

The Biopharmaceutical Excipients market report provides detailed analysis and outlook of Biopharmaceutical Excipients segments including By Chemical Component (Carbohydrates, Solubilizers and Surfactants, Polyols, Polymers, Proteins and Amino Acids), By Functionality (Buffering Agents, Lyoprotectant, Tonicity Agents, pH Adjusting Agents, Binders and Fillers), By Formulation Type (Injectable, Oral Formulations, Topical and Ophthalmic Formulations), By Scale of Operation (Preclinical, Commercial Scale), By End-User (Drug Developers, Contract Manufacturing Organizations) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biopharmaceutical Excipients Industry Overview

High-Purity Formulation Components Driving Biopharmaceutical Innovation

The biopharmaceutical excipients industry is becoming increasingly important as the development of complex biologics, monoclonal antibodies, recombinant proteins, vaccines, and advanced therapeutic products accelerates worldwide. Excipients play a critical role in maintaining drug stability, enhancing formulation performance, protecting active ingredients, and supporting long-term product integrity throughout manufacturing, storage, and administration. Growing regulatory scrutiny, rising demand for injectable biologics, and the increasing complexity of biologic formulations are encouraging manufacturers to invest in advanced excipient technologies specifically designed for high-value biopharmaceutical applications. The industry is increasingly focused on quality, purity, and supply reliability to meet evolving pharmaceutical manufacturing requirements.

Raw Material and Energy Costs Influencing Industry Dynamics

Supply chain resilience remains a major priority across the biopharmaceutical excipients sector. On March 30, 2026, BASF Pharma Solutions announced a global price increase of up to 20% across its portfolio of pharmaceutical excipients and selected active pharmaceutical ingredients. The adjustment was implemented to maintain supply chain reliability amid rising global energy expenses and increasing raw material costs. This development highlights the ongoing challenges faced by excipient manufacturers as they balance production economics with the need to ensure uninterrupted supply for pharmaceutical and biotechnology companies. As biologic drug production continues to expand, maintaining dependable excipient availability remains a strategic industry objective.

Ultra-High-Purity Excipients Supporting Injectable Biologics

A major trend shaping the biopharmaceutical excipients industry is the increasing development of ultra-high-purity surfactants and stabilizers. These advanced excipients are specifically engineered to meet stringent regulatory requirements associated with injectable biologic therapies. Manufacturers are focusing on formulations capable of preventing protein aggregation, minimizing degradation, and preserving the structural integrity of highly sensitive biologic molecules. Such excipients play a crucial role in maintaining therapeutic effectiveness and product stability throughout the product lifecycle. As biologic drugs become more complex and increasingly targeted, demand continues to rise for excipient solutions that support enhanced formulation performance and regulatory compliance.

Manufacturing Investments Expanding Biopharmaceutical Support Infrastructure

Industry participants are strengthening production capabilities and technical support infrastructure to meet growing demand from the biologics sector. BASF continues to expand its North American presence through investments such as its Good Manufacturing Practice Solution Center in Wyandotte, Michigan. The facility focuses on supplying bioprocessing ingredients and high-grade excipients specifically designed for biopharmaceutical applications. By providing specialized formulation support and GMP-compliant production capabilities, such investments enhance the availability of high-quality excipients required for advanced biologic manufacturing. The expansion of dedicated biopharmaceutical excipient infrastructure reflects the industry's commitment to supporting next-generation therapeutic development and large-scale biologics production.

Biopharmaceutical Excipients Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biopharmaceutical Excipients market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Merck KGaA, BASF SE, Evonik Industries AG, Roquette Frères, Avantor, Inc., Ashland Inc., Croda International Plc, JRS Pharma GmbH & Co. KG, Colorcon Limited, SPI Pharma, Inc.. The Biopharmaceutical Excipients market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biopharmaceutical Excipients industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biopharmaceutical Excipients Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biopharmaceutical Excipients companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biopharmaceutical Excipients markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biopharmaceutical Excipients Market Competitive Benchmarking and Company Analysis

Leading companies in Biopharmaceutical Excipients industry include- Merck KGaA, BASF SE, Evonik Industries AG, Roquette Frères, Avantor, Inc., Ashland Inc., Croda International Plc, JRS Pharma GmbH & Co. KG, Colorcon Limited, SPI Pharma, Inc.. The Biopharmaceutical Excipients market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biopharmaceutical Excipients Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biopharmaceutical Excipients market remains one of the strongest-performing segments in the country.
The US Biopharmaceutical Excipients Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biopharmaceutical Excipients market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biopharmaceutical Excipients industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biopharmaceutical Excipients markets

Canada's strong Biopharmaceutical Excipients sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biopharmaceutical Excipients market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biopharmaceutical Excipients Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biopharmaceutical Excipients market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biopharmaceutical Excipients population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biopharmaceutical Excipients industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biopharmaceutical Excipients market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biopharmaceutical Excipients sales through 2034

France Biopharmaceutical Excipients companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biopharmaceutical Excipients Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biopharmaceutical Excipients distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biopharmaceutical Excipients Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biopharmaceutical Excipients market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biopharmaceutical Excipients industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biopharmaceutical Excipients industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biopharmaceutical Excipients Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biopharmaceutical Excipients market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biopharmaceutical Excipients market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biopharmaceutical Excipients Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biopharmaceutical Excipients Market Segmentation

By Chemical Component
Carbohydrates
Solubilizers and Surfactants
Polyols
Polymers
Proteins and Amino Acids
By Functionality
Buffering Agents
Lyoprotectant
Tonicity Agents
pH Adjusting Agents
Binders and Fillers
By Formulation Type
Injectable
Oral Formulations
Topical and Ophthalmic Formulations
By Scale of Operation
Preclinical
Commercial Scale
By End-User
Drug Developers
Contract Manufacturing Organizations

Top Companies in Biopharmaceutical Excipients Industry

Merck KGaA
BASF SE
Evonik Industries AG
Roquette Frères
Avantor, Inc.
Ashland Inc.
Croda International Plc
JRS Pharma GmbH & Co. KG
Colorcon Limited
SPI Pharma, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa